Lumexa Imaging Reports Q2 2026 Earnings with Revenue Growth and Adjusted EBITDA
Lumexa Imaging (LMRI) reported second-quarter revenue of $264.2 million, a 5.1% increase compared to the same period in 2025. The company also posted adjusted EBITDA of $56.4 million with a margin of 21.4%. Advanced imaging procedures accounted for 37.4% of total system-wide volume, setting a new record and rising by over 110 basis points year-over-year. The firm reported net income of $2.7 million in Q2 compared to a loss the previous year, while free cash flow reached a record high of $23.1 million with an EBITDA conversion rate of 41%. PET procedure volume surged by 23.2% due to new equipment additions and MRI volumes rose 7.2%. Lumexa also narrowed its full-year adjusted EBITDA guidance range to between $235 million and $241 million, maintaining the midpoint at $238 million.
Topics: cash_flow ebitda revenue volume_growth